These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22371319)

  • 1. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Gururangan S; Peters KB; McLendon R; Sathornsumetee S; Rich JN; Lipp ES; Janney D; Friedman HS
    Cancer; 2012 Oct; 118(19):4759-67. PubMed ID: 22371319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    Desjardins A; Quinn JA; Vredenburgh JJ; Sathornsumetee S; Friedman AH; Herndon JE; McLendon RE; Provenzale JM; Rich JN; Sampson JH; Gururangan S; Dowell JM; Salvado A; Friedman HS; Reardon DA
    J Neurooncol; 2007 May; 83(1):53-60. PubMed ID: 17245623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
    J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Reardon DA; Norden AD; Desjardins A; Vredenburgh JJ; Herndon JE; Coan A; Sampson JH; Gururangan S; Peters KB; McLendon RE; Norfleet JA; Lipp ES; Drappatz J; Wen PY; Friedman HS
    J Neurooncol; 2012 Jan; 106(2):409-15. PubMed ID: 21938530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
    Reardon DA; Dresemann G; Taillibert S; Campone M; van den Bent M; Clement P; Blomquist E; Gordower L; Schultz H; Raizer J; Hau P; Easaw J; Gil M; Tonn J; Gijtenbeek A; Schlegel U; Bergstrom P; Green S; Weir A; Nikolova Z
    Br J Cancer; 2009 Dec; 101(12):1995-2004. PubMed ID: 19904263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
    J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
    Dresemann G; Weller M; Rosenthal MA; Wedding U; Wagner W; Engel E; Heinrich B; Mayer-Steinacker R; Karup-Hansen A; Fluge O; Nowak A; Mehdorn M; Schleyer E; Krex D; Olver IN; Steinbach JP; Hosius C; Sieder C; Sorenson G; Parker R; Nikolova Z
    J Neurooncol; 2010 Feb; 96(3):393-402. PubMed ID: 19688297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
    Chamberlain MC; Glantz MJ
    J Neurooncol; 2008 Sep; 89(2):231-8. PubMed ID: 18480965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
    Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
    J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial chemotherapy in gliomatosis cerebri.
    Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
    Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study.
    Brandes AA; Basso U; Vastola F; Tosoni A; Pasetto LM; Jirillo A; Lonardi S; Paris MK; Koussis H; Monfardini S; Ermani M
    Ann Oncol; 2003 Dec; 14(12):1727-31. PubMed ID: 14630676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
    Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
    J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
    Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
    J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
    Shah GD; Silver JS; Rosenfeld SS; Gavrilovic IT; Abrey LE; Lassman AB
    J Neurooncol; 2007 Nov; 85(2):217-22. PubMed ID: 17594055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
    Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
    Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.